The decision making process in AML integrates clinical features, an increasing amount of genetic information and minimal residual disease (MRD) data. Combining these data aims at answering the following questions:
- do I treat my patient with an intensive (= curative) or a non intensive (= non-curative) approach ?
- do I have therapeutic targets to improve the current treatment?
- is there an indication for a stem cell transplantation (SCT), maintenance therapy, etc.
Each new edition of ASH brings some new answers. This was again the case at the 2016 annual ASH meeting.
(BELG J HEMATOL 2017;8(1):29–33)